ArticleMolecular imaging and biology2020
Preclinical Safety Evaluation and Human Dosimetry of [
Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04437290 (University of Washington Alzheimer's Disease Research Center), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Trial
- Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Human biodistribution and radiation dosimetry of two novel α-synuclein PET tracers,Scientific reports · 2025Article
- Human biodistribution and radiation dosimetry for the tau tracer [EJNMMI radiopharmacy and chemistry · 2024Article
- Test-retest performance of [Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.Annals of nuclear medicine · 2023Article
- Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook.Diagnostics (Basel, Switzerland) · 2023Review
- Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.Annals of nuclear medicine · 2023Article
- A Visual Interpretation Algorithm for Assessing Brain Tauopathy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.Biomolecules · 2023Review
- Dosimetry and efficacy of a tau PET tracer [Annals of nuclear medicine · 2023Article
- Impact of meningeal uptake and partial volume correction techniques on [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Article
- 18F-MK-6240 tau-PET in genetic frontotemporal dementia.Brain : a journal of neurology · 2022Article
- PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective.Frontiers in medicine · 2022Review
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
- Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[ PROCEDURES: MK-6240 was administered intravenously (IV) in a 7-day rat toxicity study at × 50, × 100, and × 1000 dose margins relative to projected highest clinical dose of 0.333 μg/kg. The IV formulation of MK-6240 for clinical use and the formulation used in the 7-day rat toxicity study was tested for hemolysis potential in human and Wistar rat whole blood. Sequential whole-body positron emission tomography scans were performed in three healthy young subjects after IV bolus injection of 180 ± 0.3 MBq [
resultsMK-6240 administered IV in a 7-day rat toxicity study did not show any test article-related changes. The no-observed-adverse-effect level in rats was ≥ 333 μg/kg/day which provides a margin 1000-fold over an anticipated maximum clinical dose of 0.333 μg/kg. Additionally, the MK-6240 formulation was not hemolytic in human or Wistar rat blood. [
conclusionsMicrodoses of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.